Skip to main content
. Author manuscript; available in PMC: 2016 Apr 7.
Published in final edited form as: Mol Pharm. 2013 Jun 24;10(8):3164–3174. doi: 10.1021/mp4002206

Figure 4.

Figure 4

Assessment of cytotoxicity of DOX modified compounds ND2DOX (with and without MMP9 treatment) and DOX-COOH compared to DOX. A: viability of 6 µM (in DOX) ND2DOX (triangle) and 12 µM (in DOX) cleaved ND2DOX (circle) compared to 5.5 µM DOX (square). B: viability of 152 µM DOX-COOH (triangle) comared to 11 µM DOX (rhombus).